Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Capital Expenditures (2018 - 2025)

Exagen (XGN) has disclosed Capital Expenditures for 8 consecutive years, with $44000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 91.11% year-over-year to $44000.0, compared with a TTM value of $641000.0 through Dec 2025, up 24.47%, and an annual FY2025 reading of $641000.0, up 24.47% over the prior year.
  • Capital Expenditures was $44000.0 for Q4 2025 at Exagen, down from $275000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.1 million in Q1 2022 and bottomed at -$696000.0 in Q2 2022.
  • Average Capital Expenditures over 5 years is $104450.0, with a median of $99500.0 recorded in 2024.
  • Peak annual rise in Capital Expenditures hit 2370.45% in 2022, while the deepest fall reached 1580.85% in 2022.
  • Year by year, Capital Expenditures stood at $550000.0 in 2021, then tumbled by 184.18% to -$463000.0 in 2022, then plummeted by 41.68% to -$656000.0 in 2023, then surged by 175.46% to $495000.0 in 2024, then plummeted by 91.11% to $44000.0 in 2025.
  • Business Quant data shows Capital Expenditures for XGN at $44000.0 in Q4 2025, $275000.0 in Q3 2025, and $209000.0 in Q2 2025.